Drug Trial Radar · NCT07292012
Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
May 11, 2026
Primary completion
Nov 2027
Study completion Nov 2028
Sponsor
- Lead sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease
Conditions
- Crohn Disease (CD)
Interventions
Mirikizumab - IVDrug
Mirikizumab induction with IV infusions (900 mg) at week 0, week 4 and week 8.
Mirikizumab - SCDrug
SC injections (300 mg) at W12 and every 4 weeks For clinical responders and non-responders
Primary outcomes
What the sponsor says the trial is designed to measure.
- Transmural response (TR25)Time frame: From week 0 to week 24
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
CHU de Brest - Hôpital de la Cavale Blanche
Brest, France · Recruiting
CHU Caen Normandie
Caen, France · Not yet recruiting
CHU de Clermont Ferrand - Hôpital d'Estaing
Clermont-Ferrand, France · Recruiting
CHU de Nîmes Carémeau
Nîmes, France · Recruiting
Institut Mutualiste Monsouris
Paris, France · Active not recruiting
CHU Poitiers
Poitiers, France · Not yet recruiting
CHU de Toulouse - Hôpital Rangueil
Toulouse, France · Recruiting
CH de Valence
Valence, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.